For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $3.40 in the last session, down -9.09% from day before closing price of $3.74. In other words, the price has decreased by -$9.09 from its previous closing price. On the day, 0.66 million shares were traded. AMLX stock price reached its highest trading level at $3.75 during the session, while it also had its lowest trading level at $3.39.
Ratios:
We take a closer look at AMLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 4.55. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on November 18, 2024, Upgraded its rating to Outperform and sets its target price to $11 from $3 previously.
On October 23, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4.20 to $10.
Mizuho Downgraded its Buy to Neutral on March 18, 2024, whereas the target price for the stock was revised from $32 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 03 ’25 when Mazzariello Gina sold 3,678 shares for $3.49 per share. The transaction valued at 12,839 led to the insider holds 139,090 shares of the business.
Cohen Joshua B sold 11,851 shares of AMLX for $41,108 on Feb 03 ’25. The Co-Chief Executive Officer now owns 3,201,247 shares after completing the transaction at $3.47 per share. On Feb 03 ’25, another insider, Klee Justin B., who serves as the Co-Chief Executive Officer of the company, sold 11,855 shares for $3.47 each. As a result, the insider received 41,104 and left with 3,164,933 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 291348416 and an Enterprise Value of 1234724. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.48 while its Price-to-Book (P/B) ratio in mrq is 1.19. Its current Enterprise Value per Revenue stands at 0.006 whereas that against EBITDA is -0.005.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.54, which has changed by -0.7518248 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $19.95, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is -15.35%, while the 200-Day Moving Average is calculated to be 9.17%.
Shares Statistics:
According to the various share statistics, AMLX traded on average about 1.01M shares per day over the past 3-months and 926770 shares per day over the past 10 days. A total of 68.55M shares are outstanding, with a floating share count of 43.45M. Insiders hold about 36.61% of the company’s shares, while institutions hold 66.69% stake in the company. Shares short for AMLX as of 1738281600 were 2591408 with a Short Ratio of 2.45, compared to 1735603200 on 1942447. Therefore, it implies a Short% of Shares Outstanding of 2591408 and a Short% of Float of 3.26.
